trending Market Intelligence /marketintelligence/en/news-insights/trending/sdHSFsz0f7v4JaavY_M9Bw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biohaven's Alzheimer's drug passes futility analysis, moves forward in phase 2/3

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biohaven's Alzheimer's drug passes futility analysis, moves forward in phase 2/3

Biohaven Pharmaceutical Holding Co. Ltd.'s experimental treatment for Alzheimer's disease symptoms, called troriluzole, passed an interim futility analysis and will continue in its ongoing late-stage trial.

New Haven, Conn.-based Biohaven's stock ticked up by about 2.5% to $55.09 as of 2:25 p.m. ET, after reaching as high as $57.03, riding on the wave of incrementally positive Alzheimer's news coming out of the annual Clinical Trials on Alzheimer's Disease conference.

Troriluzole is in a 48-week phase 2/3 trial called T2 Protect AD, Biohaven said in its Dec. 6 press release. The trial is evaluating troriluzole's efficacy and safety against a placebo drug in patients with mild-to-moderate Alzheimer's disease.

Troriluzole is an oral drug that targets a neurotransmitter in the brain, glutamate, responsible for learning and memory, and aims to increase the neurotransmitter's activity and expression.

Had the treatment not passed its futility analysis and demonstrated numerical improvement over placebo in cognitive function and brain matter, Biohaven would have halted the T2 study early, the company said.

Just a handful of medications are approved by the U.S. Food and Drug Administration to treat symptoms of memory loss and confusion associated with Alzheimer's disease, including Allergan PLC's Namenda, or memantine, and Eisai Co. Ltd.'s Aricept, also known as a cholinesterase inhibitor. No cure has been found for Alzheimer's.

SVB Leerink analyst Marc Goodman forecast a 35% probability of success for troriluzole in Alzheimer's and predicted that the clinical trial program could wrap up in late 2020.

Goodman noted that investors had previously focused primarily on Biohaven's migraine drug candidate, rimegepant, now under FDA review, and may begin looking toward Alzheimer's.

"Investors are now starting to pay attention to AD given the news this week on ACADIA Pharmaceuticals Inc.'s Nuplazid in dementia-related psychosis and Biogen Inc.'s aducanumab," Goodman wrote Dec. 6.